210 related articles for article (PubMed ID: 11298327)
1. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
2. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
3. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
4. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
5. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
6. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
7. Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
[TBL] [Abstract][Full Text] [Related]
8. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
9. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
[TBL] [Abstract][Full Text] [Related]
12. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
Yaneva R; Springer S; Zacharias M
Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
[TBL] [Abstract][Full Text] [Related]
13. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.
Fling SP; Rak J; Muczynski KA; Arp B; Pious D
J Exp Med; 1997 Nov; 186(9):1469-80. PubMed ID: 9348304
[TBL] [Abstract][Full Text] [Related]
14. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
15. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
Denzin LK; Cresswell P
Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
[TBL] [Abstract][Full Text] [Related]
16. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
17. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.
Denzin LK; Hammond C; Cresswell P
J Exp Med; 1996 Dec; 184(6):2153-65. PubMed ID: 8976171
[TBL] [Abstract][Full Text] [Related]
18. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
19. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
20. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]